Oral Cladribine on Track to Become First Oral Disease Modifying Treatment for Multiple Sclerosis
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
GENEVA, Switzerland, January 16 /PRNewswire-FirstCall/ — Merck Serono (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety [...]